Navigation Links
Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year

EXTON, Pa., Aug. 28, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds a significant increase in the percentage of surveyed specialists who are extremely familiar with biosimilars in 2013 compared with 2012, although this group remains a minority of all physicians.

The Biosimilars Advisory Service report entitled Acceptance of Biosimilars Across Physician Specialties provides analysis of survey results from 560 physicians across six specialties in the United States and Europe. The report finds that surveyed endocrinologists are least familiar with biosimilars, with only a minority saying they are very or extremely familiar with biosimilars compared with the majority of surveyed hematologist-oncologists across all countries. On average, hematologist-oncologists and medical oncologists report significantly higher levels of familiarity compared with nephrologists and endocrinologists. From a country perspective, surveyed physicians in Germany are significantly more familiar with biosimilars than those in France, although there has been a significant increase in familiarity among French physicians this year compared with data collected in 2012.

The majority of all surveyed physicians perceive reference brands and biosimilars to be very similar to one another. Surveyed endocrinologists view biosimilars as being least similar to the reference brand; less than one half say biosimilars are very similar to the reference brand compared with two thirds of hematologist-oncologists who feel the same. The report also quantifies the correlation between physicians' level of familiarity with biosimilars and their perception of similarity between biosimilars and their reference brands.   

"Despite the availability of biosimilar somatropin plus epoetin alfa and zeta in Europe, surveyed European endocrinologists and nephrologists remain less familiar with biosimilars compared with their oncologist colleagues, although we do see marked differences by country among surveyed nephrologists," said BioTrends Research Group Senior Director, Andrew Merron, Ph.D.  "Conversely, reflecting the good acceptance of biosimilars and the relatively high level of biosimilar filgrastim uptake, surveyed European hematologist-oncologists and medical oncologists report a high level of familiarity with biosimilars. We expect this finding will contribute to a comparatively rapid uptake of complex biosimilars among oncologists compared with other specialists."

The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Online Training Course Reduces Risk for Physician Groups
2. Medtech College Recognizes Medical Billers & Coders For "Cracking The Code" Of Insurance, Patient And Physician Billing
3. New Medical Education Program Online Helps Physicians to Make The Diagnosis of Myelodysplastic Syndrome (MDS)
4. Douglas Harrington, MD Speaks At American Academy Of Physicians Assistants 2013 Conference In Washington, DC
5. The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments
6. Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS)
7. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
8. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
9. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
10. New Obesity Education Program To Premiere At American College of Physicians (ACP) Annual Meeting
11. CHI Vice President Provides Testimony On Patient, Physician Notification of Biosimilar Substitution
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):